Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.

Authors: Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir I. Vorobyev, Hang Quach, Kihyun Kim, Kazuhito Suzuki, Maria-Victoria Mateos, Jie Ma, Yinjiao Ma, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet Manasanch, Neal Sule, Brandon Kremer, Pralay Mukhopadhyay, Joanna Opalinska, Meletios Athanasios Dimopoulos

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.7515

Source: Full article

---

Abstract

7515